How the SPEAR UltraDetect™ pTau 217 assay unlocks greater discrimination of amyloid positives using 1 µL of diluted sample

A new case study from Dr. Thomas Karikari (University of Pittsburgh) demonstrates how the SPEAR UltraDetect^™ pTau217 assay delivers superior discrimination of amyloid-positive vs. amyloid-negative individuals using just 1 μL of diluted plasma. Compared with Simoa^® ALZpath and Lumipulse^® assays across two independent cohorts, the SPEAR assay showed higher accuracy, larger effect sizes, and exceptional robustness, even with samples subjected to multiple freeze–thaw cycles. The work highlights how the assay enables reliable pTau217 quantification from precious or limited biobanked samples, expanding possibilities for Alzheimer’s disease research.